CD27 Ligand

CD27 Ligand

CD27 Ligand Informations sur la molécule

Molecule Name
CD70 antigen
Alias de la molécule
CD70,CD27LG,TNFSF7,TNFSF7G,CD27L
Drug Development Progress
Nombre de médicaments cliniques37
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
CD70 antigen,Surface Antigen CD70,LPFS3,CD27L,Tumor necrosis factor ligand superfamily member 7,CD27LG,CD27-L,CD70,CD70 Molecule,TNFSF7,Tumor Necrosis Factor (Ligand) Superfamily, Member 7,Tumor Necrosis Factor Ligand 8A,Ki-24 Antigen,TNLG8A,CD27 Ligand
Contexte de la molécule
Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

CD27 Ligand Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Plateforme de commerce de projets d'anticorps

Nom du projetPhase du projetType de moléculeSource de moléculeDomain thérapeutiqueIndication
CD70 VHH - 01LeadMonoclonalNanobodyHematological MalignancyNon-hodgkin lymphoma
Nom du projet
CD70 VHH - 01
Phase du projet
Lead
Type de molécule
Monoclonal
Source de molécule
Nanobody
Domain thérapeutique
Hematological Malignancy
Indication
Non-hodgkin lymphoma